Sunday 22 April 2018 - 18:07
PMA (TPA) Purity: HPLC Tests Show Six Vendors Have Incorrect Purity Claims for Their PMA -- March 28, 2018
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
A-5959 Azacitidine, Free Base, >99%
Synonyms : [5-AzaC] [5-Azacytidine] [5-AZC] [5-AZCR] [5-Azacitidine] [Azacitidinum] [Ladakamycin] [Ledakamycin] [U 18496] [WR 183027]
Related Terms : [Mylosar] [Vidaza]
- Size
- US $
- €
- £
- ¥
- 100 mg
- 37
- 30
- 26
- 4,000
- In stock
- 200 mg
- 64
- 51
- 45
- 6,900
- In stock
- 250 mg
- 75
- 60
- 53
- 8,100
- In stock
- 500 mg
- 112
- 90
- 79
- 12,100
- In stock
- 1 g
- 167
- 135
- 119
- 18,000
- In stock
- 2 g
- 252
- 204
- 179
- 27,100
- In stock
- 5 g
- 445
- 361
- 317
- 47,900
- In stock
- 10 g
- 680
- 552
- 485
- 73,200
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 244.20
- C8H12N4O5
- [320-67-2]
- Azacitidine is a chemical analog of cytidine, a nucleoside found in DNA and RNA. It inhibits DNA methyltransferase and leads to hypomethylation in the promoter region of transcriptionally silenced genes. Azacytidine demonstrated significant cytotoxicity against both conventional therapy-sensitive and therapy-resistant multiple myeloma (MM) cell lines, as well as multidrug-resistant patient-derived MM cells, with IC50 values of approximately 0.8-3 μM. Azacytidine treatment induced DNA double-strand breaks and apoptosis of MM cells. Kiziltepe T., et al. "5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells." Mol. Cancer Ther. 6: 1718-1727 (2007).
- Azacitidine is the active ingredient in the drug product sold under the trade names Mylosar and Vidaza®. This drug is currently approved in at least one country for use in patients with myelodysplastic syndrome. NOTE: THE AZACITIDINE, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT MYLOSAR OR VIDAZA®, AND IS NOT FOR HUMAN USE.
- Related CAS numbers: 879492-75-8 for the methanesulfonate salt; 1401238-96-7 for the sulfate salt; 1401238-97-8 for the hydrobromide salt.
- Other CAS numbers previously assigned to 5-Azacitidine, Free Base, namely 52934-49-3 and 292869-98-8, have been deleted by CAS and are no longer in use.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.